PHF6 and acute myeloid leukemia: Even after exclusion of AML‐MRC‐M cases, PHF6 mutations retained their association with improved OS (HR 0.06, 95% CI 0.006–0.69, p = 0.024) and EFS (HR 0.06, 95% CI 0.006–0.65, p = 0.020), while NRAS mutations retained their association with improved EFS (HR 0.44, 95% CI 0.21–0.91, p = 0.028) in multivariable analysis (data not shown).